Current management of MF. This algorithm represents our approach to the management of MF with some considerations on COVID-19, SCT selection, anemia-oriented treatments, and risk-based strategy to control clinical needs of patients. CBC, complete blood count; CI, cormorbidity index; Dan, danazol; del, deletion; EPO, erythropoietin; ESAs, erythropoiesis stimulating agents; FEDR, fedratinib; HU, hydroxyurea; JAKis, JAK inhibitors; Len, lenalidomide; MF, myelofibrosis; MonoAb, monoclonal antibody; MTD, maximum tolerated dose; PAC, pacritinib; PEG-IFN, PEGylated-interferon; PLT, platelets; PS, performance status; RBC, red blood cells; RUX, ruxolitinib; SCT, stem cells transplant; Thal, thalidomide; tx, treatment. ¹As for DIPSS/apex (Dynamic International Prognostic Scoring System) or MIPSS-70/apexV2 (Mutation-Enhanced International Prognostic Scoring System) or MYSEC-PM (Myelofibrosis Secondary to polycythemia vera and essential thrombocythemia-Prognostic Model. ²Low, intermediate and selected high-risk MTSS (Myelofibrosis Transplant Scoring System) cases.